Graybug Vision, Inc. (GRAY)

NASDAQ: GRAY · IEX Real-Time Price · USD
0.824
-0.020 (-2.39%)
At close: Jun 24, 2022 4:00 PM
0.840
+0.016 (1.966%)
After-hours: Jun 24, 2022 4:04 PM EDT
-2.39%
Market Cap 17.60M
Revenue (ttm) n/a
Net Income (ttm) -34.52M
Shares Out 21.36M
EPS (ttm) -1.62
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 87,624
Open 0.830
Previous Close 0.844
Day's Range 0.820 - 0.869
52-Week Range 0.720 - 7.060
Beta n/a
Analysts Buy
Price Target 3.19 (+287.2%)
Earnings Date Aug 10, 2022

About GRAY

Graybug Vision, Inc., a clinical-stage biopharmaceutical company, focuses on the development of medicines for the treatment of diseases of the retina and optic nerve. The company's lead product candidate is GB-102, an intravitreal injection of a microparticle depot formulation of sunitinib that is in Phase I/IIa and IIb clinical trials for the treatment of wet age-related macular degeneration, as well as in Phase IIa clinical trial to treat diabetic macular edema. It also develops GB-102, for the treatment of diabetic retinopathy; and GB-401, a... [Read more...]

Industry Biotechnology
IPO Date Sep 25, 2020
Employees 27
Stock Exchange NASDAQ
Ticker Symbol GRAY
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 11 analysts, the average rating for GRAY stock is "Buy." The 12-month stock price forecast is 3.19, which is an increase of 287.23% from the latest price.

Price Target
$3.19
(287.23% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Graybug to Present Clinical Development Plan Update for GB-102 at the 2022 Clinical Trials at the Summit Meeting

BALTIMORE, May 19, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of ocular dis...

Graybug to Present Preclinical Data for GB-401 in Primary Open-Angle Glaucoma at the 2022 ARVO Annual Meeting

BALTIMORE, April 27, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of ocular d...

Graybug to Present at the 2022 ASCRS Annual Meeting

BALTIMORE, April 18, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of ocular d...

Graybug Vision Appoints Dirk Sauer to Board of Directors

BALTIMORE, April 13, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of ocular d...

Graybug Announces Pipeline Expansion, Current Cash Expected to Deliver Three Clinical Readouts in 2023

BALTIMORE, March 30, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of ocular d...

Graybug Vision to Host Virtual R&D Day on March 30, 2022

BALTIMORE, March 21, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of ocular d...

Graybug Vision Reports Full Year 2021 Financial Results and Recent Corporate Developments

Management to host R&D Day for investors on March 30, 2022 at 11 a.m. ET Management to host R&D Day for investors on March 30, 2022 at 11 a.m. ET

Graybug to Participate in Three Upcoming Medical and Investor Conferences

BALTIMORE, Feb. 03, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of diseases ...

Graybug Vision Makes Key Hires to Further Build Momentum Behind its Pipeline

BALTIMORE, Jan. 20, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of diseases ...

Graybug Vision Announces Financial Results for the Three and Nine Months Ended September 30, 2021, and Recent Corpora...

BALTIMORE, Nov. 11, 2021 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of diseases ...

Graybug Vision to Participate in the American Academy of Ophthalmology 2021 Annual Meeting

BALTIMORE, Nov. 01, 2021 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of diseases ...

Graybug Vision to Participate in the Annual Ophthalmology Innovation Summit (OIS) Retina@ASRS Conference

BALTIMORE, Sept. 30, 2021 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of diseases...

Graybug Vision Reports Analysis of Data from the Six-Month Extension Study of the ALTISSIMO Phase 2b Trial in Wet AMD

BALTIMORE, Sept. 28, 2021 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of diseases...

Graybug Vision to Participate in the Cantor Virtual Global Healthcare Conference

BALTIMORE, Sept. 21, 2021 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of diseases...

Graybug Vision Announces Financial Results for the Three and Six Months Ended June 30, 2021, and Recent Corporate Dev...

REDWOOD CITY, Calif., Aug. 11, 2021 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment o...

Graybug Vision to Participate in the 2021 Wedbush PacGrow Healthcare Virtual Conference

REDWOOD CITY, Calif., Aug. 04, 2021 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment o...

Is the Options Market Predicting a Spike in Graybug Vision (GRAY) Stock?

Investors need to pay close attention to Graybug Vision (GRAY) stock based on the movements in the options market lately.

Graybug Vision Shorts Got A Serious Squeeze: What's Next?

Graybug Vision Inc (NASDAQ: GRAY) has not released any news since it printed its first-quarter 2021 earnings results May 12, but that didn't stop the stock from closing up 22% on Thursday and soaring fu...

Graybug Vision Reports Full Data Analysis After One Year Treatment Of GB-102 In Wet AMD

Graybug Vision Inc (NASDAQ: GRAY) has provided full-data analysis from the 12-month treatment Phase of its Phase 2b ALTISSIMO trial evaluating GB-102 to treat wet age-related macular degeneration (wet A...

Graybug Vision Announces First Quarter 2021 Financial Results and Recent Corporate Developments

REDWOOD CITY, Calif., May 12, 2021 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of...

Why Is Graybug Vision Stock Plunging Today?

Graybug Vision Inc (NASDAQ: GRAY) shares are dropping after preliminary data from Phase 2b ALTISSIMO trial of GB-102 for wet age-related macular degeneration (wet AMD). Investors are reacting to the mea...

Graybug Vision Reports Preliminary Topline Results from Phase 2b ALTISSIMO Trial

REDWOOD CITY, Calif., March 09, 2021 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment ...

Graybug Vision Announces Full Year 2020 Financial Results and Recent Corporate Developments

REDWOOD CITY, Calif., March 04, 2021 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment ...

Graybug Vision to Participate in SVB Leerink Global Healthcare Conference

REDWOOD CITY, Calif., Feb. 17, 2021 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines to treat chronic vi...

Graybug Vision Appoints Bettina Maunz as Chief People Officer, Expanding the Company's Executive Team

REDWOOD CITY, Calif., Feb. 01, 2021 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines to treat chronic vi...